Patents Assigned to Parker Hughes Institute
  • Dual function microbicides
    Patent number: 6774139
    Abstract: Contraceptive activity as well as anti-microbial, particularly anti-viral protection is provided by contraceptive compositions containing a thiourea compound of the invention exhibiting spermicidal or sperm-immobilizing activity. Preferred compounds of the invention are cyclohexenyl-substituted thiourea compounds.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: August 10, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Osmond D'Cruz
  • BTK inhibitors and methods for their identification and use
    Patent number: 6753348
    Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors, including allergy treatments.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: June 22, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Ravi Malaviya
  • Vanadium compounds for treating cancer
    Patent number: 6743786
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: June 1, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
  • Platinum (II) antitumor compounds
    Patent number: 6737537
    Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: May 18, 2004
    Assignee: Parker Hughes Institute
    Inventors: Faith M. Uckun, Rama K. Narla
  • Cytotoxic compounds
    Patent number: 6734207
    Abstract: Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: May 11, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Shyi-Tai M. Jan
  • Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections
    Patent number: 6727265
    Abstract: The invention provides compounds which inhibit reverse transcriptase (RT) and which inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The compound of the invention are phenoxyethyl-thiourea-pyridines. The invention additionally provides a method for inhibiting reverse transcriptase activity of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention. The invention additionally provides a method for inhibiting replication of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: April 27, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • 6,7-Dimethoxyquinazolines and therapeutic use thereof
    Publication number: 20040039002
    Abstract: Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.
    Type: Application
    Filed: June 5, 2003
    Publication date: February 26, 2004
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu, Rama Krishna Narla
  • Inhibitors of thrombin induced platelet aggregation
    Publication number: 20040034045
    Abstract: The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits JAK-3 and/or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerbrovascular diseases.
    Type: Application
    Filed: May 29, 2003
    Publication date: February 19, 2004
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Piperidinylethyl-, phenoxyethyl-, and &bgr;-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity
    Patent number: 6689793
    Abstract: The present invention is directed to derivatives of piperidinylethyl, phenoxyethyl, and fluorophenethyl bromopyridyl thioureas, which have been found to be effective non-nucleoside inhibitors (NNRTI) of NNI-resistant and multi-drug resistant human immunodeficiency virus (HIV)-1 reverse transcriptase (RT). The present invention is further directed to methods of using the above derivatives to treat patients with NNI-resistant or multi-drug resistant human immunodeficiency virus (HIV)-1.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: February 10, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Cathepsin inhibitors in cancer treatment
    Publication number: 20040005329
    Abstract: Embodiments of the present invention provide methods for inhibiting tumor cell growth, or treating cancer cells, in a subject through the administration of a cathepsin inhibitor or inhibitors. Methods for inhibiting inflammatory disease cells as well as other cathepsin expressing cells in a subject with a cathepsin inhibitor or inhibitors are also within the present invention. Furthermore, the present invention relates to inducing cytotoxicity or apoptosis in cells by administering a cytotoxic or an apoptotic dose of a cathepsin inhibitor or inhibitors to the cell. Finally, the present invention relates to the administering of cathepsin expressing vectors to tumor cells so as to inhibit the tumor cells growth.
    Type: Application
    Filed: July 2, 2003
    Publication date: January 8, 2004
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, De-Min Zhu
  • Ikaros isoforms and mutants
    Publication number: 20040002096
    Abstract: Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematologic malignancy, are also provided.
    Type: Application
    Filed: March 21, 2003
    Publication date: January 1, 2004
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Mya L. Crotty
  • Aryl phosphate derivatives of d4T having anti-HIV activity
    Patent number: 6670336
    Abstract: Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. In a preferred aspect of the present invention, the phosphorus of the aryl phosphate group is further substituted with an amino acid residue that may be esterified or substituted, such as a methoxy alaninyl group.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: December 30, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rakesh Vig
  • Vanadium (IV) complexes containing catecholate ligand and having spermicidal activity
    Patent number: 6667339
    Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: December 23, 2003
    Assignee: Parker Hughes Institute
    Inventors: Phalguni Ghosh, Faith M. Uckun, Osmond D′Cruz
  • Aromatic and heterocyclic thiazolyl thiourea compounds and use
    Publication number: 20030207921
    Abstract: Novel aromatic and heterocyclic thiazolyl thiourea compounds, pharameutical compositions including such, and methods for their use are disclosed. The compounds are effective agents for the treatment of HIV infection, including non-nucleoside inhibitor-resistant, and multi-drug resistant strains of HIV.
    Type: Application
    Filed: April 15, 2003
    Publication date: November 6, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Vanadium compounds as anti-proliferative agents
    Patent number: 6642221
    Abstract: Vanadium compounds as anti-proliferative agents. These compounds act to disrupt mitotic and meiotic spindle formation and thus are useful to prevent cell mitosis (proliferation) and meiosis.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: November 4, 2003
    Assignee: Parker Hughes Institute
    Inventors: Faith M Uckun, Christopher S Navara
  • 6,7-dimethoxyquinazolines and therapeutic use thereof
    Patent number: 6638939
    Abstract: Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: October 28, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu, Rama Krishna Narla
  • Inhibitors of thrombin induced platelet aggregation
    Patent number: 6635651
    Abstract: The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits JAK-3 and/or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerbrovascular diseases.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: October 21, 2003
    Assignee: Parker Hughes Institute
    Inventor: Faith M. Uckun
  • Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections
    Publication number: 20030186991
    Abstract: The invention provides compounds which inhibit reverse transcriptase (RT) and which inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The compound of the invention are phenoxyethyl-thiourea-pyridines. The invention additionally provides a method for inhibiting reverse transcriptase activity of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention. The invention additionally provides a method for inhibiting replication of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention.
    Type: Application
    Filed: April 15, 2003
    Publication date: October 2, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Vanadium (IV) metallocene complexes having spermicidal activity
    Patent number: 6627655
    Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, including their corresponding therapeutic compositions are described.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: September 30, 2003
    Assignee: Parker Hughes Institute
    Inventors: Osmond D'Cruz, Phalguni Ghosh, Fatih M. Uckun
  • R-isomers of nonnucleoside inhibitors
    Publication number: 20030181717
    Abstract: Novel chiral derivitaves of non-nucleoside inhibitors (NNI), particularly R-isomers of halopyridyl and thiazoyl thiourea compounds are provided as potent inhibitors of reverse transcriptase (RT), and particularly of retroviral RT, most particularly HIV RT. The stereospecific compounds and compositions of the invention inhibit replication of retrovirus, particularly human immunodeficiency virus-1 (HIV-1) and drug resistant strains.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 25, 2003
    Applicant: Parker Hughes Institute located at Roseville, Minnesota
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam